Moderna

Moderna Shares Surge as U.S. Cancer Vaccine Push Lifts Biotech Sentiment

Moderna shares jumped sharply after reports that the United States is preparing a national cancer vaccine initiative, fueling investor bets that mRNA technology could gain a major new policy tailwind. The move pushed the stock to a four-year high and reignited debate over whether government backing could accelerate the commercial path for cancer immunotherapy platforms.